Biocept, Inc.
2151 Las Palmas Drive
Suite C
Carlsbad
California
92009
United States
Tel: 760-804-9580
Fax: 760-804-6238
Website: http://www.biocept.com/
Email: kbrown@biocept.com
387 articles about Biocept, Inc.
-
Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer
2/10/2022
Biocept has appointed Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer.
-
Biocept Reports an Increase in COVID-19 RT-PCR Testing Volume with Spread of the Omicron Variant
1/21/2022
Biocept, Inc announces that COVID-19 RT-PCR testing volume has increased in 2022 with the emergence of the Omicron variant.
-
Biocept to Present at the H.C. Wainwright BioConnect Virtual Conference on January 10
1/4/2022
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.
-
Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain
12/9/2021
Biocept, Inc presented a study demonstrating the ability of its CNSide™ assay to identify HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease (LMD).
-
Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season
11/22/2021
Biocept, Inc. now offers a single test that can detect and distinguish between SARS-CoV-2 and influenza, helping patients and caregivers determine appropriate treatment decisions.
-
Clinical Validation is Completed for New COVID-19 Assay Designed by AEGEA Biotechnologies; Test Quantifies Viral Load to Determine Infection Level and Disease Progression
11/22/2021
AEGEA Biotechnologies, Inc., an innovative life science company with an extensive portfolio of next-generation nucleic acid technologies, announces that the new PCR-based COVID-19 assay it designed has been validated by Biocept, Inc., a leading provider of molecular diagnostic assays, products and services.
-
CORRECTING and REPLACING Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
11/18/2021
Breast cancer is one of the most common cancers associated with LMD, a devastating complication in which cancer spreads to the membrane surrounding the brain and spinal cord.
-
Biocept’s CNSide Cerebrospinal Fluid Assay Aids in Monitoring Treatment Response and Detects Actionable Biomarkers in Patients with Metastatic Breast Cancer
11/18/2021
Biocept, Inc. (Nasdaq: BIOC), today announced the presentation of a multi-institutional case series showing that its CNSide™ cerebrospinal fluid assay helps physicians monitor treatment response and detects actionable mutations in patients with metastatic breast cancer and leptomeningeal disease (LMD).
-
Biocept Reports Third Quarter 2021 Financial Results
11/15/2021
Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update.
-
Study Shows Biocept’s Switch-Blocker Technology Enhances Performance of Conventional PCR-Based Liquid Biopsy Assays in Detecting Rare Cancer Mutations
11/9/2021
Biocept, Inc today announced the publication of a study showing that the addition of Switch-Blocker™ technology to common PCR-based liquid biopsy assays significantly increased sensitivity in detecting rare cancer mutations.
-
Biocept to Report Third Quarter 2021 Financial Results and Host Investor Conference Call on November 15, 2021
11/8/2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three and nine months ended September 30, 2021 after the market closes on Monday, November 15, 2021.
-
Biocept to Present at the LD Micro Main Event on October 13
10/6/2021
Biocept, Inc will present a company overview at the LD Micro Main Event on Wednesday, October 13, 2021 at 11:00 a.m. Pacific time (2:00 p.m. Eastern time).
-
Biocept Implements COVID-19 Testing Program at Select California Community Colleges, Supporting Testing Needs for Students and Staff Amid Pandemic
9/22/2021
Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, has implemented its COVID-19 testing services at more than 30 community college campuses across California, streamlining the testing and tracking process for administrators, and allowing students and staff to easily schedule and complete COVID-19 testing.
-
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations
9/21/2021
Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-Blocker TM Technology to Detect Rare Cancer Mutations
-
Biocept to Present at Four Virtual Investor Conferences in September 2021
9/7/2021
Biocept, a leading provider of molecular diagnostic assays and services, announces that Michael Nall, President and CEO, will present at four upcoming investor conferences.
-
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2021
9/1/2021
Biocept, a leading provider of molecular diagnostic assays and services, announced that it has granted inducement stock options to purchase an aggregate of 220,800 shares of its common stock to 16 new employees.
-
Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
8/19/2021
Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer
-
Biocept Reports Second Quarter 2021 Financial Results
8/16/2021
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2021 and provides a business update.
-
Biocept to Report Second Quarter 2021 Financial Results and Host Investor Conference Call on August 16, 2021
8/9/2021
Biocept, Inc. announces that it will release financial results for the three and six months ended June 30, 2021 after the market closes on Monday, August 16, 2021. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
-
Biocept Names David Karlander as Senior Vice President of Commercial Operations
8/3/2021
Biocept has appointed David Karlander as Senior Vice President of Commercial Operations.